NCT01557127已完成不适用
Nexavar Dose Evaluation Study in Patients With Advanced Renal Cell Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 205
- 主要终点
- Percentage of patients in whom the actual dose of sorafenib equaled the planned dose
研究概览
简要总结
This study is a registry of renal cancer patients treated with Nexavar. It aims to evaluate the actual dosing of Nexavar in "real-life" setting vs. the prescribed dose.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age >/= 18 years
- •Diagnosis of renal cell carcinoma
- •Failure of prior therapy with interferon-alfa (IFN) or interleukine-2 (IL-2) or disqualified from therapy with IFN/IL-2
- •Patients in whom the oncologist has decide to start therapy with sorafenib.
排除标准
- •Synonymous with contraindications to Nexavar.
研究组 & 干预措施
Group 1
干预措施: Sorafenib (Nexavar, BAY43-9006) (Drug)
结局指标
主要结局
Percentage of patients in whom the actual dose of sorafenib equaled the planned dose
时间窗: 12 months
次要结局
- Overall tolerability of treatment as measured by rate of adverse events(12 months)
研究者
相似试验
已完成
不适用
Nexavar Post-marketing Surveillance for RCC in Japan: Early Access ProgramCarcinoma, Renal CellNCT01412671Bayer117
已完成
不适用
A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ®Carcinoma, Renal CellCarcinoma, Renal Cell (Advanced)NCT00771147Bayer71
已完成
不适用
A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.Renal Cell CancerCancer of KidneyCancer of the KidneyKidney CancerKidney NeoplasmsRenal CancerRenal Cell CarcinomaNCT05363072Pfizer1,112
已完成
2 期
Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous InvasionMetastatic Renal Cell CarcinomaNon-metastatic Renal Cell CarcinomaRenal Cell CarcinomaNCT03494816Scottish Clinical Trials Research Unit24
已完成
不适用
Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell CarcinomaCarcinoma, Renal CellNCT01508364Bayer20